Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | +3.63% | +12.36% | -86.41% |
11/04 | Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating | MT |
10/04 | Transcript : Amylyx Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.41% | 131M | |
-3.76% | 86.16B | |
+2.76% | 40.17B | |
-17.49% | 31.47B | |
+54.44% | 25.24B | |
-13.13% | 15.82B | |
-9.12% | 11.96B | |
-15.45% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |
- Stock Market
- Equities
- AMLX Stock
- News Amylyx Pharmaceuticals, Inc.
- Amylyx Pharmaceuticals Reports Narrowed Q3 Net Loss, Small Increase in Revenue